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ABSTRACT:  
Background & Aims: Poorly digested, fermentable carbohydrates may induce symptoms of 
irritable bowel syndrome (IBS), via unclear mechanisms. We performed a randomized trial 
with magnetic resonance imaging (MRI) analysis to investigate correlations between 
symptoms and changes in small and large bowel contents following oral challenge. 
 
Methods: We performed a 3-period crossover study of 29 adult patients with IBS (based on 
Rome III criteria, with symptoms of abdominal pain or discomfort for at least 2 days/week) 
and reported bloating. In parallel we performed the same study of 29 healthy individuals 
(controls). Studies were performed in the United Kingdom from January 2013 through 
February 2015. On 3 separate occasions (at least 7 days apart), subjects were given a 500 
ml drink containing 40 g of carbohydrate (glucose in the first period, fructose in the second, 
and inulin in the third, in a random order). Levels of breath hydrogen were measured and 
intestinal content was assessed by MRI before and at various time points after consumption 
of each drink. Symptoms were determined based on subjects’ responses to the Hospital 
Anxiety and Depression Scale questionnaire and the Patient Health Questionnaire-15. The 
primary endpoint was whether participants had a clinically important symptom response 
during the 300 minutes following consumption of the drink. 
 
Results: More patients with IBS reached the pre-defined symptom threshold after intake of 
inulin (13/29) or fructose (11/29) than glucose (6/29). Symptoms peaked sooner after intake 
of fructose than inulin. Fructose increased small bowel water content in both patients and 
controls whereas inulin increased colonic volume and gas in both. Fructose and inulin 
increased breath hydrogen levels in both groups, compared to glucose; fructose produced 
an earlier increase than inulin. Controls had lower symptom scores during the period after 
drink consumption than patients with IBS, despite similar MRI parameters and breath 
hydrogen responses. In patients who reached the symptom threshold after inulin intake, 
peak symptom intensity correlated with peak colonic gas (r = 0.57; P<0.05). Changes in MRI 
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features and peak breath hydrogen levels were similar in patients who did and did not reach 
symptom threshold.  
 
Conclusions: Patients with IBS and healthy individuals without IBS (controls) have similar 
physiological responses following intake of fructose or inulin; patients more frequently report 
symptoms after inulin than controls. In patients with a response to inulin, symptoms relate to 
levels of intra-luminal gas, but peak gas levels do not differ significantly between responders, 
non-responders or controls. This indicates that colonic hypersensitivity to distension, rather 
than excessive gas production, produces carbohydrate-related symptoms in patients with 
IBS. Clinicaltrials.gov no: NCT01776853 
 
KEY WORDS: FODMAP; bloating; fermentation; MRI 
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Background & Aims   
Most patients with the irritable bowel syndrome (IBS) report that certain foods can 
exacerbate symptoms1. Identifying the components of food responsible for symptoms has 
proved difficult. The concept of food allergy was popular but is now recognised to affect only 
a small proportion of IBS sufferers in most general gastroenterology clinics2. The role of bran 
and fibre has been debated for many years with evidence of benefit in constipation3 but 
aggravation of other symptoms such as flatulence4. More recently there has been renewed 
interest in a role for short-chain, poorly digested, fermentable carbohydrates termed 
fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). 
Evidence of a link between dietary FODMAPs and symptoms comes from a double-blind 
crossover study exposing IBS patients to escalating intake of either glucose, fructose, 
oligofructose or a mixture of the latter two for up to 2 weeks5. Fructose or oligofructose were 
significantly more likely than glucose to induce symptom recurrence. A subsequent 
crossover study found that patients reported fewer symptoms following a low FODMAP diet 
compared to a typical Australian diet6. A UK study found that low FODMAP dietary advice 
was more efficacious than standard dietary advice for IBS though it should be noted that this 
was not placebo controlled7. More recently a randomised comparison found no difference 
between a low FODMAP and an empirical "IBS diet" based on healthy eating patterns, low 
fat content and avoidance of beans, cabbage and onions 8. 
While evidence regarding efficacy continues to accrue, less work has been published on the 
mechanisms by which dietary changes may affect symptoms. FODMAPs are believed to 
induce symptoms by two principal mechanisms. The ‘small bowel’ hypothesis contends that 
unabsorbed, osmotically active carbohydrates draw water into the small bowel, as has been 
previously demonstrated with lactose in the context of lactase deficiency9. This causes 
distension with symptoms of bloating and discomfort. The increased small bowel water 
content also accelerates oro-caecal transit, reducing small bowel absorption. The ‘large 
bowel’ hypothesis proposes that rapid colonic fermentation of unabsorbed carbohydrates 
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generates gas, distending the colon and causing flatulence, bloating and discomfort. Reports 
that some IBS patients have different microbiota to non-sufferers10, 11, and that the 
microbiota changes with diet,12, 13 suggest that the metabolic output of the microbiota such 
as hydrogen (H2) and other gases may be important  mediators in the symptom response to 
both FODMAPs and the low FODMAP diet. Equally, evidence for visceral hypersensitivity in 
a subset of IBS patients suggests that the same magnitude of stimulus will produce different 
degrees of symptom response in patients depending on their sensory threshold14.    
Measurement of luminal physiology has previously relied on invasive techniques such as 
manometry or barostat, or imaging techniques requiring ionising radiation such as 
scintigraphy or computed tomography. Wireless capsules have added new insights15 but 
cannot provide concurrent recording from the whole intestine. Recent advances in magnetic 
resonance imaging (MRI) allow assessment of the luminal environment without disturbing 
the system under investigation or using ionising radiation, a particularly advantageous 
feature in the substantial proportion of IBS patients who are young and female16.  Application 
of MRI to measurement of small bowel water content has been validated17 and used to 
demonstrate the osmotic effects of mannitol18 and lactulose19 in IBS patients and healthy 
volunteers. Assessment of colonic content is feasible but requires prior definition of its 
volume using approaches commonly applied to imaging of solid viscera20, 21. Luminal gas 
has been assessed in both the small bowel22 and colon23.  
A recent study used a combination of these approaches to assess the differential effects of 
two poorly digested/ absorbed carbohydrates, inulin and fructose, on intestinal content in 
healthy subjects23. Inulin, an osmotically inactive polysaccharide with a high degree of 
polymerisation (DP), was used to investigate exclusively large bowel effects and induced an 
increase in colonic gas not seen with glucose. The monosaccharide fructose is variably 
absorbed and osmotically active, and in this study led to a profound increase in small bowel 
water content compared to glucose. The study excluded volunteers with a history of bowel 
disorders so was unable to comment on any relationship between physiological responses to 
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carbohydrate ingestion and symptoms. Volunteers were also predominantly male and 
younger than the typical IBS population. 
The aim of the current study was to investigate whether poorly digested/ absorbed 
carbohydrates would lead to symptoms in more IBS patients than a glucose control, and 
which changes in intestinal content would correlate best with IBS symptoms.  We also 
sought to look for objective differences in luminal content between patients and a parallel 
sample of volunteers without IBS, frequency-matched to the IBS sample for age and gender.  
Methods 
Design 
A three-period, three treatment crossover trial recruiting patients with IBS and bloating 
(Patient study), with a parallel cohort of healthy volunteers without functional gastrointestinal 
symptoms (Volunteer study) following the same trial regimen. The studies were approved by 
the United Kingdom National Research Ethics Service and prospectively registered on 
www.clinicaltrials.gov (NCT01776853). The trial ran from January 2013 to February 2015. A 
prospective amendment to the primary endpoint is described below and was the only 
material change to the published protocol.  All authors had access to the study data and 
reviewed and approved the final manuscript. 
Participants 
All participants were adults aged 18-65. Patients were included if they met Rome III research 
criteria for IBS, reporting symptoms of abdominal pain/ discomfort for at least two days per 
week, and reported bloating as a frequent symptom. We chose such patients since it is 
these symptoms which respond best to the low FODMAP diet and hence it is this group of 
patients where there is most interest in the impact of fructose and fructans. Volunteers were 
included if they reported symptoms no more than once per month. An upper age limit was 
used to limit any effect of undiagnosed diverticular disease. Exclusion criteria included 
gastrointestinal (GI) surgery other than resection of the appendix or gall bladder, inability to 
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stop drugs known to alter GI motility for the duration of the study or contraindication to MRI 
scanning. No interventions were administered within 4 weeks of antibiotic use. Patients were 
recruited through tertiary and secondary clinics in Nottingham, from a departmental 
database of patients prepared to take part in research and through open advertisement 
including the department’s social media presence. All clinic patients had undergone 
appropriate screening following current guidelines and had normal haematological and 
biochemical values, negative coeliac serology and normal colonoscopy and biopsy if 
diarrhoea was a feature. Bile acid malabsorption, lactose malabsorption and pancreatic 
insufficiency were excluded where relevant. Those recruited through other routes had all 
been given a positive diagnosis by their general practitioner having had symptoms for more 
than 6 months. All such candidates completed a 7-day stool and symptom diary in addition 
to the Rome III questionnaire. Volunteers were recruited in a similar manner. 
Interventions and Procedures 
The treatments administered were 500mL drinks consisting of 40 grams of carbohydrate 
dissolved in water, flavoured with 25mL lemon juice, to be consumed in 15 minutes. The 
carbohydrates used were: a) ‘glucose’ - dextrose monohydrate (DP = 2) sold as Dextrose 
Powder (Thornton & Ross, Huddersfield, UK); b) ‘fructose’ - 100% fructose (DP = 1) sold as 
Fruit Sugar Pure Fructose (Holland & Barrett, Nuneaton, UK); c) ‘inulin’ - OraftiHP, ≥99% 
chicory-derived inulin (DP ≥ 23) supplied initially as a gift by Orafti (Belgium) then purchased 
from Beneo (Mannheim, Germany).  
At enrolment all participants completed two questionnaires: the Hospital Anxiety and 
Depression Scale (HADS) and the Patient Health Questionnaire (PHQ)-15 from which we 
calculated the PHQ-12 by excluding the 3 GI-related questions24. Participants then attended 
3 treatment days separated by at least one week to minimise any carryover effect. 
Participants were asked to moderate their diet for a full day before a treatment day, avoiding 
onion, garlic, pickles, sauces and other UK specific foods known to be high in fructans. 
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Honey, jams, chocolates and other foods known to be high in fructose were also excluded. 
Bakery and dairy alternatives were also recommended to reduce intake of non-glucose 
carbohydrates.  Participants fasted from 8pm in the evening and remained nil by mouth from 
waking on the treatment day. Treatment days took place at the Sir Peter Mansfield Magnetic 
Resonance Centre. 3 modes of assessment were used: symptom questionnaire, H2 breath 
testing and MRI. Non-alcoholic mouthwash was administered prior to any breath testing. All 
3 assessments were performed prior to the test drink and at 0, 60, 120, 180, 240 and 300 
minutes after its consumption. Symptoms and breath H2 were also assessed at 30 and 90 
minutes.  
Randomisation and Blinding 
All participants took all treatments in the crossover design. The order of treatment was 
allocated according to a schedule randomly generated without blocking using Stata v13 by a 
member of the department not directly involved in the study delivery. The randomisation 
schedule was held by the departmental team of healthcare support workers responsible for 
preparing drinks who were independent of the study. All drinks were made with boiled water 
and then chilled to ensure standardisation. Both investigators and participants were blind to 
the intervention on each day. Analysis of MRI data was undertaken blind to challenge drink, 
symptoms and breath H2 readings. All entries into the study database were made prior to 
unblinding.  
Endpoints 
The primary endpoint was defined as whether participants reached a threshold of a ‘clinically 
important symptom response’ (yes/ no) during the 300 minutes following the drink. Clinical 
response was measured by a Composite Symptom Score including 4 symptoms: gas/ 
flatulence; bloating; pain/ discomfort; diarrhoea. Diarrhoea was included to reflect a 
consensus that fermentable carbohydrates cause increased water content of stool through 
osmotic pressure.  At each time point each symptom was scored as 0 (none); 1 (mild/ 
negligible); 2 (moderate/ annoying); 3 (severe/ disabling). This score reflected previously 
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used scoring systems25-27, including those applied to assess the effect of fructose and inulin 
on GI symptoms28, 29, and addressed patients’ conceptual framework for IBS30.   
The aim of the threshold was to avoid false assignment of importance to diurnal variation in 
the symptoms commonly experienced by both patients and the general population. We 
judged that a CSS ≥3 would have face validity as clinical important. Review of data from our 
previous study23 in healthy volunteers found that 1/16 met this threshold for each 
intervention used, making it a plausible cut-off to discriminate a signal due to the test drink 
from background noise. A study published during the trial reporting high levels of baseline 
symptoms in IBS patients31 demonstrated the need to measure the increase in symptoms, 
not just an absolute score. The threshold for the primary endpoint was therefore amended 
from an absolute score to a rise in CSS (CSS) ≥3.  
Secondary endpoints addressed physiological effects of the drinks. Breath H2 was measured 
in parts per million (ppm) using the Gastrolyzer device (Bedfont, UK). MRI measurements 
included small bowel water content (SBWC, mL), colonic volume (mL) and colonic gas 
(arbitrary units, au). ’Symptom intensity’ was measured using a composite of visual analogue 
scales (0-100) for each symptom as described by Skoog et al.28. This second symptom 
measurement was used to provide more finely graded assessment for quantitative analysis.  
MRI data analysis 
All images were acquired using a whole-body 1.5T scanner (Achieva, Philips Medical 
System, Best, The Netherlands). The methods for measurement of SBWC and colonic 
volume have been described in detail previously17, 20. The sigmoid colon,  is normally 
collapsed and not included in the measurement of the descending colon, however in this 
study it was noted to often be markedly distended and so was measured by our usual 
technique, as has recently been shown to be feasible by other groups32. Ultimately 36/ 58 
individuals had a measurable sigmoid colon for at least one time point, and in 20/58 this was 
more than 50mL, values which were included in the total colon volume.  Colonic gas was 
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measured using the following objective algorithm: using the data acquired for colonic volume 
measurements, the MRI analyst selected an index region of interest within a clearly defined 
pocket of gas in the colon. This pocket provided a mean(M) and standard deviation (SD) to 
define objectively the image intensity of gas. Areas within the colon were defined as gas 
where 5 or more adjoining voxels had an intensity ≤ M+2SD. To reduce inter-observer 
variability a single experienced operator analysed all data from the small bowel (KM) and 
colon (SP).     
Sample size and Statistical Analysis 
The primary efficacy comparison was the difference in proportion of patients meeting the 
primary endpoint (CSS ≥3). Each test intervention (fructose, inulin) was compared to 
glucose control (McNemar’s test).  
Secondary endpoints were compared using the area under the curve (AUC) of the change 
from baseline in the period 0-300 minutes following the drink. Each test intervention was 
compared to glucose control. Paired differences were assessed for normality by the Shapiro-
Wilk test, confirmation of which permitted analysis by paired t-test for each intervention 
against control. Exploratory comparisons between patients and controls were made by Chi-
squared test for the primary endpoint and unpaired t-test for other endpoints.  All analyses 
were undertaken using SPSS version 20 (IBM, USA). Results are presented without 
correction for multiple comparisons. 
The sample size was estimated in order to address the primary efficacy comparison in 
patients based on past literature and pilot data described earlier. It was predicted that 10% 
of patients would meet primary endpoint after glucose and that a response rate of 40% after 
fructose or inulin would be noteworthy. No data was available on within-person correlation. 
With power set as 80% and a significance level of 0.05 a range of within-person correlations 
were modelled suggesting a sample size of 23 – 35. Allowing for withdrawal, a sample size 
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of 35 in each study was estimated to allow collection of 30 complete MRI data sets, the 
criteria for participants to be included for analysis in this mechanistic study. 
Given the variation between individual symptom profiles against time, further exploratory 
analysis to assess correlations between physiological variables and symptoms used the 
peak rise from baseline in symptom intensity. 
Results 
29 participants completed each study. Details of exclusions and withdrawals are included in 
the supplementary information. After assessment by the Rome III questionnaire 5 patients 
met criteria for diarrhoea-predominant IBS, 6 for constipation-predominant IBS and 18 for 
mixed type. The demographics and psychological scores of participants and volunteers were 
similar, other than somatisation scores, and are summarised in Table 1. 
Table 1: Demographics of participants in Patient and Volunteer studies 
Primary endpoint 
6/29 (21%) patients reached the symptom threshold (CSS ≥3) after the glucose control, a 
higher rate than predicted. 13/29 (45%) reached symptom threshold after inulin, a 
significantly higher proportion than after glucose (P < 0.05). The response rate was also 
somewhat higher after fructose (11/29, 38%) but not significantly so. In patients who reached 
threshold median time to peak symptom intensity was shorter (P = 0.06) with fructose (90 
mins, n =11) than with inulin (240 mins, n =13). Volunteer response rates were lower for 
inulin at 3/29 (P <0.01) and 3/29 for fructose (P <0.05). 2/29 reached symptom threshold for 
glucose which was not significantly less than in the patient cohort. The paired results for 
patients and controls are summarised in Table 2. 
Table 2: Contingency tables of subjects reaching primary endpoint (CSS ≥3) 
Secondary endpoints 
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One patient’s colonic images were not interpretable because of extremely large amounts of 
gas throughout the study so these were excluded from analysis. Two patients did not record 
a breath hydrogen reading >20ppm at any point during the trial, suggesting a lack of 
hydrogen-producing bacteria. Data for area under the curve of the change from baseline for 
each variable are presented by intervention in Table 3 with time course data in Figure 1. In 
both studies the AUC for breath H2 and colonic volume was higher for both fructose and 
inulin than for glucose. In both studies the AUC for SBWC was higher after fructose than 
glucose, while the AUC for colonic gas was higher after inulin. In patients colonic gas was 
also increased after fructose but to a lesser degree (P < 0.05).  
 
AUC for symptom intensity was higher in patients after both interventions and in volunteers 
after inulin compared to glucose (P <0.05). The degree of change in intensity of symptoms 
tended to be higher in patients than in volunteers (Figure 1A). 
The patterns of change in the physiological variables were similar for both patients and 
volunteers (P > 0.1 for all, Figure 1B-E). After inulin changes in all variables followed a 
similar time course. Time to peak breath H2 was significantly shorter (P <0.001) after 
fructose (mean 108 mins, 95% CI 84 – 132, n = 58) than after inulin (mean 266 mins, 95% 
CI 249 – 283, n = 58), although the magnitude of change was higher after inulin (Table 3). 
The time course of fructose-induced changes in SBWC followed the same pattern as breath 
H2 but peaked significantly (P <0.001) sooner (mean 44 mins, 95% CI 33 – 56, n = 58). The 
decline in breath H2 after 120 minutes diverged from the increase in colonic volume and gas 
seen at the same time. Subjective assessment of MRI sequences measuring SBWC noted 
high water content in the colon (Figure 2) but this variable was not specifically measured as 
the signal from fluid entering the colon is transient and fades variably over time. 
Table 3:  Postprandial change from baseline for secondary endpoints (Mean SEM) 
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Figure 1: Time series of symptom intensity and physiological variables for each 
intervention in Patients and Volunteers. 
Top – patient data; Bottom – volunteer data. Panel A: Symptom intensity; Panel  B: Breath 
hydrogen; Panel C: Small bowel water content; Panel D: Colonic gas; E: Colonic volume.  
 
Figure 2: Example of MRI analysis showing colonic water shortly after fructose 
A: unprocessed T2-weighted image; B: detectable free water after threshold applied; C: 
anatomical image for comparison  
 
Correlations between physiology and symptoms 
The data from patients who met primary endpoint were explored for correlations between 
peak rise from baseline in physiological parameters and peak rise in symptom intensity. For 
the 12 patients with symptoms after inulin and usable colonic data, the best correlate was 
peak rise in colonic gas (Pearson’s r = 0.57, n = 12, P < 0.05, Figure 3). No significant 
correlation was seen with SBWC (r = -0.1, n = 13) nor breath H2   (r = 0.26, n = 13). In the 11 
patients with symptoms after fructose correlations were weaker although both peak rise in 
SBWC and breath H2 showed a non-significant relationship (r = 0.51, n =11, P = 0.11 for 
both).  Too few healthy volunteers met primary endpoint for meaningful analysis. 
Figure 3: Correlation between peak rise in colonic gas and peak rise in symptom 
intensity after inulin (n = 12) 
Lastly, the inulin data were explored for differences in the peak rise in colonic gas between 
subjects who did and did not reach the symptom threshold after inulin. No difference was 
seen between patients who did and did not report symptoms. In contrast the few healthy 
volunteers who reached threshold after inulin had peak rises in colonic gas at the top of the 
range for all subjects. Changes in colonic volume followed a similar pattern in both studies. 
Individual data points are shown in Figure 4. For fructose, the only variable that showed 
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some difference between subjects who did and did not report symptoms was their initial 
score on the PHQ-12 questionnaire, measuring somatisation (P <0.05, Mann-Whitney). 
Responders to fructose had higher PHQ-12 scores (median 8, IQR 7 – 12) than did non-
responders (median 5, IQR 3 – 8), where a normal score is defined as less than 7. 
 
Figure 4: Comparison of peak rise in colonic content between those who did and did 
not meet symptom threshold (CSS ≥3) 
A: Colonic gas; B: Colonic volume 
 
Discussion 
The study is the first to use MRI to compare the effects of poorly digested, fermentable 
carbohydrates on symptoms and physiology in IBS. The most notable findings were those 
relating to inulin. 40g of inulin induced more patients to reach our pre-determined symptom 
threshold than did 40g of glucose. Inulin induced greater increases in breath H2, colonic gas 
and colonic volume. The time courses of change in those physiological variables and 
symptom intensity were similar. In those who reported symptoms above threshold, peak rise 
in symptom intensity correlated with peak rise in colonic gas but not colonic volume or breath 
H2. We did not measure breath methane, another gas that may have contributed to colonic 
expansion, but in our experience only a small proportion of subjects produce only methane 
so this would be unlikely to alter our conclusions. However in IBS patients the magnitude of 
peak increases of gas on MRI in those who exceeded the symptom threshold had a similar 
range to those who did not.  The study therefore offered no evidence that patients who 
reported symptoms produced more colonic gas than those who did not. Those patients with 
a higher peak in breath hydrogen were no more likely to report symptoms with inulin or 
fructose, in agreement with other studies suggesting that the utility of a breath test to predict 
response to dietary fructose exclusion is limited33, 34. An alternative hypothesis would be that, 
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as has been shown with lactose malabsorption35, the patients with symptoms had a lower 
sensory threshold for reporting.  
Some healthy volunteers reported mild symptoms, principally flatulence, but few exceeded 
our pre-determined symptom threshold despite physiological changes similar to those seen 
in IBS. Those few that did had a peak rise in colonic gas that was at the top end of the range 
in the sample. This would be consistent with the concept that the colon normally 
accommodates gas without symptoms unless particularly large volumes are produced. Any 
trial to test this formally, with a similar event rate, would need to recruit a far larger sample.  
The findings in relation to fructose are more complex to interpret. Firstly, the difference in 
symptom response to fructose and glucose was not as clear cut as for inulin. The event rate 
in the glucose control period was higher than predicted, and higher than the event rate in 
either the healthy volunteer pilot study23 or the parallel volunteer study reported here. 
Previous studies suggest that the colonic motor response to feeding is calorie dependent 
and would normally require a much bigger load of glucose than the 40g we gave36. Exactly 
what stimulus the patients are responding to is therefore unclear. It may reflect expectation 
and an increased tendency in IBS patients to report symptoms without any differences in 
sensitivity, as described by Dorn et al.14. Previous studies have found higher symptom rates 
with fructose in IBS patients but any inference drawn about the mechanisms of effect of 
fructose requires the caveat that differences in the primary endpoint from glucose control 
may have been due to chance alone. The higher degree of somatisation, as reflected by the 
PHQ-12 scores, in patients who did and did not report symptoms supports the idea that 
somatisation is related to visceral hypersensitivity as Dorn et al reported. We did not formally 
assess visceral hypersensitivity using a barostat but such studies could further validate MRI 
as a non-invasive measure of hypersensitivity to the stimulus of food related intestinal 
distension, which is most likely the everyday stimulus which causes pain in IBS patients. 
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The size and time course of changes in small bowel water (SBWC) were similar to the initial 
study of Murray et al. and were seen in both study groups. Also noted were significant 
increases in breath H2 and colonic volume. Breath H2 levels peaked after SBWC and 
remained mildly elevated for several hours, presumably reflecting the small amount of 
fructose that escapes absorption and enters the colon. Nevertheless the increase in colonic 
volume cannot be solely attributed to colonic gas and may include increased influx of ileal 
fluid associated with increased SBWC. However, none of the variables measured in the 
study correlated strongly with symptom intensity nor showed large differences between 
those who did and did not exceed the symptom threshold. Where present, symptoms after 
fructose did peak earlier than after inulin, suggesting that small bowel distension might 
cause symptoms albeit not a sufficiently large effect to detect a signal with the sample size 
used here.  
As such this study provides no evidence that poorly digested carbohydrates generate 
symptoms directly through small bowel distension. If there is a subset of patients who suffer 
symptoms as a result of small bowel liquid distension, then this would likely be due to 
abnormal motor patterns leading to a failure to disperse the fluid load through the length of 
the small bowel, with consequent local distension. There is an inherent challenge to the 
generation of such evidence while excluding any effect from subsequent colonic 
mechanisms. The absorption of fructose varies considerably between patients which 
reduces the power of our study to show a link with symptoms.  Further work using non-
absorbable sugars such as lactulose19 may be needed to tease out the role of the small 
bowel. Zhu et al. have recently reported on the response to lactose in a Chinese population 
with a high prevalence of lactose maldigestion, where rectal hypersensitivity assessed by 
barostat was associated with a higher odds ratio for bloating (6.61, 95% CI 1.75 – 25) than 
was hydrogen production (2.19, 95% CI 1.1 – 4.4)37. Our results are consonant with these 
findings.  
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Our study had limitations. The diagnosis of IBS was confirmed in patients using a clinical 
standard of care, in keeping with the principle of making a positive diagnosis. Other GI 
disorders may present as IBS although UK data suggest that presentation with coeliac 
disease, colorectal cancer or inflammatory bowel disease in the year following diagnosis is a 
rare event38. There is increasing interest in the role of small intestinal bacterial overgrowth in 
IBS. All participants in the study underwent a de facto glucose hydrogen breath test during 
the study. None met local diagnostic criteria for overgrowth, set at a rise from baseline of 
>20ppm. One asymptomatic volunteer recorded a rise in breath hydrogen of 15ppm. Small 
bowel aspirate and culture is rarely performed in the UK unless there are signs of 
malabsorption such as anaemia which none of our patients had.  Participants had lower 
scores for anxiety and depression than we have previously reported in patients largely 
recruited from secondary care 24. This may reflect our recruitment procedures which included 
patients in primary care and those who responded to advertisement. Specialist referral may 
reflect failure of coping strategies for patients and non-specialists, which may be associated 
with worse mental health. Our sample may therefore be more reflective of IBS sufferers in 
the general population. 
We did not account for variation in regular diet of participants, nor did we exclude patients 
who had used a low FODMAP diet. To do so may have biased our sample in either direction: 
such patients may be more likely to incur symptoms when exposed to FODMAPs, or less 
likely if dietary modification leads to alterations in their microbiota with consequent changes 
in its carbohydrate metabolism. The longitudinal interactions between diet, microbiota, 
physiology and symptoms are still being elucidated and were beyond the scope of this work. 
The patient study was not powered to account for such a frequent symptom response to 
drinking a glucose solution. This is most likely a nocebo response since the patient 
information sheet made it clear that one or more of the solutions might induce symptoms. An 
advantage of the crossover design is that any effect is only attributed to the test drink in 
patients who did not report symptoms after glucose. The unusual circumstances of the MRI 
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centre may have exacerbated psychological distress but no effect of visit order was 
identified. Nevertheless, future studies will need to account better for the glucose response 
rate when calculating their sample size. As this was the first MRI study on this topic in 
patients we used frequent scanning over an extended period and so resource constraints 
meant that it was not feasible to study large numbers of patients. Now we have provided 
information on the time scale of changes, future studies can use more efficient protocols to 
provide increased power to detect smaller differences in effect size. 
In addition the reductionist approach taken, using carbohydrate solutions, may not induce 
the full range of physiological response seen with a food product. Food composition may 
alter interaction with the microbiota on arrival in the colon. Chronic exposure may lead to 
alterations in the microbiota and subsequent physiological response. MRI data are not 
available to assess changes occurring after 5 hours. Future studies will need to look at the 
effect of smaller, chronic changes in fructose and fructan intake in order to understand the 
role of diet over time. 
The analysis reported here combines the small and large bowel into single units. Symptoms 
may also relate to changes at focal points in the bowel, such as the flexures and sigmoid 
colon, which was not captured by the regional assessments made.  There may also be 
variation between IBS subtypes. While all patients reported bloating, they had different stool 
habits which may reflect differences in pathophysiology. While there may be common 
pathways underlying bloating and discomfort across the IBS spectrum, future studies should 
consider reducing heterogeneity by focusing on one subtype.  
The strength of the study is the unique insight that it provides on the undisturbed luminal 
environment during periods of symptoms. Traditional methods for assessing visceral 
sensitivity rely on invasive techniques such as the barostat. Such techniques inevitably alter 
the psychological state of the subject so may indirectly, and indeed directly change the 
visceral response. No invasive device was used in this study: the only interventions were 
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drinks, breath tests and scans.  The double-blind crossover design reduced bias in the 
interpretation of the differential effects of the drinks. While no formal comparisons between 
the patient and volunteer studies are presented, the physiological response appeared to be 
similar between the groups and confirmed that the changes seen in our original paper in 
younger healthy volunteers also occurred in samples of volunteers of IBS patients with 
similar age and gender mix to the typical IBS population. Inulin reliably induced colonic 
distension and in the future may provide a standard stimulus with which to study visceral 
sensitivity.  
In conclusion this study demonstrates a mechanism by which dietary carbohydrates that are 
poorly digested and then fermented induce symptoms of the irritable bowel syndrome. 
Patients experiencing symptoms did not have greater gas production or visceral distension 
but the degree of gas produced did correlate with the intensity of symptoms. This supports 
the hypothesis that visceral hypersensitivity is the reason that some IBS patients report 
symptoms after eating FODMAP-containing foods, and symptom relief when following a low 
FODMAP diet. 
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